Anna Teti

List of Publications by Year
in descending order

103 papers	7,403 citations	53794 45 h-index	54911 84 g-index
104 all docs	104 docs citations	104 times ranked	9019 citing authors

#	Article	IF	Citations
1	Insulin Signaling in Osteoblasts Integrates Bone Remodeling and Energy Metabolism. Cell, 2010, 142, 296-308.	28.9	957
2	Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nature Genetics, 2007, 39, 960-962.	21.4	346
3	Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone Formation. Journal of Cell Biology, 2000, 151, 311-320.	5.2	275
4	Impaired skeletal development in interleukinâ€6â€“transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. Arthritis and Rheumatism, 2006, 54, 3551-3563.	6.7	271
5	Genetics, pathogenesis and complications of osteopetrosis. Bone, 2008, 42, 19-29.	2.9	240
6	Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone, 2009, 44, 11-16.	2.9	208
7	Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. Journal of Clinical Investigation, 2007, 117, 919-930.	8.2	204
8	Chloride Channel ClCN7 Mutations Are Responsible for Severe Recessive, Dominant, and Intermediate Osteopetrosis. Journal of Bone and Mineral Research, 2003, 18, 1740-1747.	2.8	202
9	Immunocytochemical distribution of extracellular matrix receptors in human osteoclasts: A Î²3 integrin is colocalized with vinculin and talin in the podosomes of osteoclastoma giant cells. Experimental Cell Research, 1989, 182, 645-652.	2.6	197
10	The Great Beauty of the osteoclast. Archives of Biochemistry and Biophysics, 2014, 558, 70-78.	3.0	173
11	Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nature Medicine, 2009, 15, 674-681.	30.7	172
12	Bone metastasis: pathogenesis and therapeutic implications. Clinical and Experimental Metastasis, 2007, 24, 599-608.	3.3	132
13	A Six-Gene Signature Predicting Breast Cancer Lung Metastasis. Cancer Research, 2008, 68, 6092-6099.	0.9	131
14	Inhibition of Protein Kinase c-Src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice: Implications for Therapy. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 161-172.	2.5	126
15	Isolated osteoclasts in primary culture: first observations on structure and survival in culture media. Anatomy and Embryology, 1982, 165, 405-413.	1.5	117
16	Mechanisms inducing low bone density in duchenne muscular dystrophy in mice and humans. Journal of Bone and Mineral Research, 2011, 26, 1891-1903.	2.8	116
17	Osteoblast-Derived Extracellular Vesicles Are Biological Tools for the Delivery of Active Molecules to Bone. Journal of Bone and Mineral Research, 2018, 33, 517-533.	2.8	105
18	Bone Development: Overview of Bone Cells and Signaling. Current Osteoporosis Reports, 2011, 9, 264-273.	3.6	103

#	Article	IF	Citations
19	Genotype-Phenotype Relationship in Human ATP6i-Dependent Autosomal Recessive Osteopetrosis. American Journal of Pathology, 2003, 162, 57-68.	3.8	97
20	Kinase-Dependent and -Independent Roles of EphA2 in the Regulation of Prostate Cancer Invasion and Metastasis. American Journal of Pathology, 2009, 174, 1492-1503.	3.8	96
21	Modeled microgravity stimulates osteoclastogenesis and bone resorption by increasing osteoblast RANKL/OPG ratio. Journal of Cellular Biochemistry, 2007, 100, 464-473.	2.6	93
22	c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling. Nature Communications, 2012, 3, 630.	12.8	93
23	Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer, 2014, 14, 154.	2.6	92
24	Imbalance of Osteoclastogenesis-Regulating Factors in Patients With Celiac Disease. Journal of Bone and Mineral Research, 2004, 19, 1112-1121.	2.8	91
25	Recent Advances in Mesenchymal Stem Cell Immunomodulation: The Role of Microvesicles. Cell Transplantation, 2015, 24, 133-149.	2.5	91
26	Characterization of the osteoblast-like cell phenotype under microgravity conditions in the NASA-approved rotating wall vessel bioreactor (RWV). Journal of Cellular Biochemistry, 2002, 85, 167-179.	2.6	90
27	Osteoclast receptors and signaling. Archives of Biochemistry and Biophysics, 2008, 473, 147-160.	3.0	83
28	Osteopenia, decreased bone formation and impaired osteoblast development inSox4heterozygous mice. Journal of Cell Science, 2007, 120, 2785-2795.	2.0	80
29	Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocrine-Related Cancer, 2006, 13, 197-210.	3.1	79
30	Osteoblast conditioned media contain TGF-?1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. , 1999, 81, 395-403.		78
31	Lipocalin 2: A New Mechanoresponding Gene Regulating Bone Homeostasis. Journal of Bone and Mineral Research, 2015, 30, 357-368.	2.8	76
32	Parathyroid hormone binding to cultured avian osteoclasts. Biochemical and Biophysical Research Communications, 1991, 174, 1217-1222.	2.1	73
33	The glycosaminoglycan-binding domain of PRELP acts as a cell typeâ€“specific NF-ÎºB inhibitor that impairs osteoclastogenesis. Journal of Cell Biology, 2009, 187, 669-683.	5.2	72
34	Deregulation of the IL-1Î² axis in chronic recurrent multifocal osteomyelitis. Pediatric Rheumatology, 2014, 12, 30.	2.1	71
35	Mechanisms of osteoclast-dependent bone formation. BoneKEy Reports, 2013, 2, 449.	2.7	70
36	A New Heterozygous Mutation (R714C) of the Osteopetrosis Gene, Pleckstrin Homolog Domain Containing Family M (With Run Domain) Member 1 (PLEKHM1), Impairs Vesicular Acidification and Increases TRACP Secretion in Osteoclasts. Journal of Bone and Mineral Research, 2008, 23, 380-391.	2.8	69

#	Article	IF	Citations
37	Inhibition of Protein Kinase c-Src as a Therapeutic Approach for Cancer and Bone Metastases. Anti-Cancer Agents in Medicinal Chemistry, 2008, 8, 342-349.	1.7	69
38	Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone, 2004, 34, 65-79.	2.9	67
39	Global transcriptome analysis in mouse calvarial osteoblasts highlights sets of genes regulated by modeled microgravity and identifies a â€œmechanoresponsive osteoblast gene signatureâ€. Journal of Cellular Biochemistry, 2009, 107, 240-252.	2.6	63
40	A novel protein kinase C Î±-dependent signal to ERK1/2 activated by Î±VÎ²3 integrin in osteoclasts and in Chinese hamster ovary (CHO) cells. Journal of Cell Science, 2005, 118, 3263-3275.	2.0	60
41	Osteoblast-derived TGF-Î²1 modulates matrix degrading protease expression and activity in prostate cancer cells. International Journal of Cancer, 2000, 85, 407-415.	5.1	59
42	Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry. British Journal of Cancer, 2019, 121, 157-171.	6.4	59
43	Receptor Activator of NF-ÎºB Ligand Enhances Breast Cancerâ€“Induced Osteolytic Lesions through Upregulation of Extracellular Matrix Metalloproteinase Inducer/CD147. Cancer Research, 2010, 70, 6150-6160.	0.9	54
44	Osteopetroses, emphasizing potential approaches to treatment. Bone, 2017, 102, 50-59.	2.9	53
45	Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. International Journal of Cancer, 1998, 77, 82-93.	5.1	52
46	Novel C16orf57 mutations in patients with Poikiloderma with Neutropenia: bioinformatic analysis of the protein and predicted effects of all reported mutations. Orphanet Journal of Rare Diseases, 2012, 7, 7.	2.7	48
47	Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles. Journal of Endocrinology, 2006, 191, 287-299.	2.6	45
48	Expanding the role of Src and protein-tyrosine phosphatases balance in modulating osteoblast metabolism: Lessons from mice. Biochimie, 2010, 92, 327-332.	2.6	44
49	Mechanisms of Osteoclast Dysfunction in Human Osteopetrosis: Abnormal Osteoclastogenesis and Lack of Osteoclast-Specific Adhesion Structures. Journal of Bone and Mineral Research, 1999, 14, 2107-2117.	2.8	43
50	Interaction of estrogen receptor Î± with protein kinase C Î± and c-Src in osteoblasts during differentiation. Bone, 2004, 34, 100-111.	2.9	43
51	Tartronates: A New Generation of Drugs Affecting Bone Metabolism. Journal of Bone and Mineral Research, 1997, 12, 972-981.	2.8	42
52	Colony Stimulating Factor-1-Induced Osteoclast Spreading Depends on Substrate and Requires the Vitronectin Receptor and the c-src Proto-Oncogene. Journal of Bone and Mineral Research, 1998, 13, 50-58.	2.8	42
53	Kinome profiling of osteoblasts on hydroxyapatite opens new avenues on biomaterial cell signaling. Biotechnology and Bioengineering, 2014, 111, 1900-1905.	3.3	42
54	Beta₃Subunit of Vitronectin Receptor is Present in Osteoclast Adhesion Structures and Not in Other Monocyte-Macrophage Derived Cells. Connective Tissue Research, 1989, 20, 143-149.	2.3	40

#	Article	IF	Citations
55	CLCN7 and TCIRG1 Mutations Differentially Affect Bone Matrix Mineralization in Osteopetrotic Individuals. Journal of Bone and Mineral Research, 2014, 29, 982-991.	2.8	38
56	The â€œloveâ€“hateâ€•relationship between osteoclasts and bone matrix. Matrix Biology, 2016, 52-54, 176-190.	3.6	38
57	Î²-Arrestin2 Regulates RANKL and Ephrins Gene Expression in Response to Bone Remodeling in Mice. Journal of Bone and Mineral Research, 2009, 24, 775-784.	2.8	37
58	Reprint of: The Great Beauty of the osteoclast. Archives of Biochemistry and Biophysics, 2014, 561, 13-21.	3.0	37
59	Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models. Bone, 2014, 59, 66-75.	2.9	36
60	A Novel Calcium Sensor Stimulating Inositol Phosphate Formation and [Ca2+]i Signaling Expressed by GCT23 Osteoclast-Like Cells. Proceedings of the Association of American Physicians, 1999, 111, 70-81.	2.0	35
61	Osteopontin Modulates Prostate Carcinoma Invasive Capacity through RGD-Dependent Upregulation of Plasminogen Activators. Biological Chemistry, 2002, 383, 229-234.	2.5	33
62	Polymorphisms of the CLCN7 Gene Are Associated With BMD in Women. Journal of Bone and Mineral Research, 2005, 20, 1960-1967.	2.8	31
63	Design of novel three-phase PCL/TZâ€“HA biomaterials for use in bone regeneration applications. Journal of Materials Science: Materials in Medicine, 2010, 21, 2569-2581.	3.6	30
64	Osteoblast-osteoclast relationships in bone resorption: Osteoblasts enhance osteoclast activity in a serum-free co-culture system. Biochemical and Biophysical Research Communications, 1991, 179, 634-640.	2.1	29
65	Transforming growth factor-Î² enhances adhesion of melanoma cells to the endotheliumin vitro. , 1997, 72, 1013-1020.		28
66	Calcitonin Increases Cytosolic Free Calcium Concentration via Capacitative Calcium Influx. Journal of Biological Chemistry, 1995, 270, 16666-16670.	3.4	27
67	In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human breast cancer cells. Bone, 2004, 34, 697-709.	2.9	27
68	Oligodeoxynucleotide Targeted to the Î±v Gene Inhibits Î±v Integrin Synthesis, Impairs Osteoclast Function, and Activates Intracellular Signals to Apoptosis. Journal of Bone and Mineral Research, 1999, 14, 1867-1879.	2.8	26
69	Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs. Journal of Bone and Mineral Research, 2012, 27, 2387-2398.	2.8	24
70	Apparent Cure of a Newborn with Malignant Osteopetrosis Using Prednisone Therapy. Journal of Bone and Mineral Research, 2001, 16, 2356-2360.	2.8	23
71	Biotechnological approach for systemic delivery of membrane Receptor Activator of NF-ÎºB Ligand (RANKL) active domain into the circulation. Biomaterials, 2015, 46, 58-69.	11.4	23
72	Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss. Journal of Bone and Mineral Research, 2013, 28, 1912-1924.	2.8	21

#	Article	IF	Citations
73	Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2. Molecular Therapy - Nucleic Acids, 2015, 4, e248.	5.1	21
74	Differentially expressed genes in autosomal dominant osteopetrosis type II osteoclasts reveal known and novel pathways for osteoclast biology. Laboratory Investigation, 2014, 94, 275-285.	3.7	20
75	RNA interference therapy for autosomal dominant osteopetrosis type 2. Towards the preclinical development. Bone, 2018, 110, 343-354.	2.9	20
76	Translocation of protein kinase C isoenzymes by elevated extracellular Ca2+ concentration in cells from a human giant cell tumor of bone. Bone, 1995, 17, 175-183.	2.9	19
77	NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains. Molecular Biology of the Cell, 2012, 23, 2028-2040.	2.1	19
78	Osteoclasts and hematopoiesis. BoneKEy Reports, 2012, 1, 46.	2.7	18
79	The C-Terminal Domain of Chondroadherin: A New Regulator of Osteoclast Motility Counteracting Bone Loss. Journal of Bone and Mineral Research, 2014, 29, 1833-1846.	2.8	17
80	Protein Kinase C Modulates Estrogen Receptors in Differentiated Osteoblastic Cells In Vitro. Steroids, 1998, 63, 352-354.	1.8	16
81	Osteoblast-derived TGF?-1 modulates matrix degrading protease expression and activity in prostate cancer cells. , 2000, 86, 888-888.		16
82	Collagen VII expression in glomerular sclerosis. Journal of Pathology, 2001, 195, 383-390.	4.5	16
83	Immediate cell signal induced by laminin in rat Sertoli cells. Matrix Biology, 2000, 19, 11-18.	3.6	15
84	The effects of parathyroid hormone or 1,25-dihydroxyvitamin D3 on monocyte-osteoclast fusion. Calcified Tissue International, 1988, 42, 302-308.	3.1	14
85	The Physiology and Pathophysiology of the Osteoclast. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 71-97.	0.8	14
86	Phospholipase D- and Protein Kinase C Isoenzyme-Dependent Signal Transduction Pathways Activated by the Calcitonin Receptor. Endocrinology, 1998, 139, 3241-3248.	2.8	14
87	Bone, a dynamic and integrating tissue. Archives of Biochemistry and Biophysics, 2014, 561, 1-2.	3.0	13
88	The Î±2Î²1 binding domain of chondroadherin inhibits breast cancer-induced bone metastases and impairs primary tumour growth: A preclinical study. Cancer Letters, 2015, 358, 67-75.	7.2	13
89	Congenital disorders of bone and blood. Bone, 2019, 119, 71-81.	2.9	13
90	Modulation of human estrogen receptor Î± F promoter by a protein kinase C/c-Src-dependent mechanism in osteoblast-like cells. Journal of Molecular Endocrinology, 2006, 37, 489-502.	2.5	12

#	Article	IF	Citations
91	Extra-skeletal manifestations in mice affected by Clcn7-dependent autosomal dominant osteopetrosis type 2 clinical and therapeutic implications. Bone Research, 2019, 7, 17.	11.4	12
92	Osteoblasts Regulate Angiogenesis in Response to Mechanical Unloading. Calcified Tissue International, 2019, 104, 344-354.	3.1	12
93	Osteoclast Isolation: New Developments and Methods. Journal of Bone and Mineral Research, 1999, 14, 1251-1252.	2.8	11
94	Committed osteoclast precursors colonize the bone and improve the phenotype of a mouse model of autosomal recessive osteopetrosis. Journal of Bone and Mineral Research, 2010, 25, 106-113.	2.8	11
95	Metaplasic Bone Tissue in Tympanosclerosis. Acta Oto-Laryngologica, 1983, 95, 554-559.	0.9	7
96	Isolation and Generation of Osteoclasts. Methods in Molecular Biology, 2019, 1914, 3-19.	0.9	7
97	Modulation of Estrogen Receptor Levels in Mouse Uterus by Protein Kinase C Isoenzymes. Endocrinology, 1998, 139, 4598-4606.	2.8	4
98	Bone remodeling: Facts and perspectives. Archives of Biochemistry and Biophysics, 2008, 473, 97.	3.0	3
99	The central role of the skeleton in chronic diseases. Archives of Biochemistry and Biophysics, 2010, 503, 1.	3.0	3
100	Transcriptomic and bioinformatic analysis of Clcn7-dependent Autosomal Dominant Osteopetrosis type 2. Preclinical and clinical implications. Bone, 2021, 144, 115828.	2.9	3
101	Haematopoietic Stem Cell Transplantation in Autosomal Recessive Osteopetrosis. , 2013, , 267-288.		2
102	Role of Stem Cell Niche in the Development of Bone Metastases (An Update). , 2013, , 229-238.		0
103	Osteoclast Determinants and Implications for Therapy. , 2013, , 121-130.		0